PROTOCOL SPECIFIC RESEARCH The Protocol Specific Research program provides data management and other infrastructure support of novel clinical trials designed and implemented by Kimmel Cancer Center members. These trials are innovative, early phase (I or II), and/or pilot studies testing concepts that are likely to lead to expanded, externally funded studies. Since the last grant submission, the investigators at the Kimmel Cancer Center have been committed to the development of investigator-initiated trials. Institutional funds cover experienced support staff for these trials. Funds are being requested to provide financial support for additional clinical research coordinators for the planned investigator initiated trials (IIT). The area of greatest emphasis has been in the development of innovative """"""""first-in-man"""""""" trials of new agents, in conjunction with therapeutic radiation. These trials are conducted with multi-disciplinary leadership including radiation oncologists, medical oncologists, surgical oncologists, and translational scientists. Over the last 6 years, the number of these trials has increased from 3 to 9 active trials. The 9 multi-modality IIT currently open accounted for 60% of the cancer center therapeutic accrual during 2006. As of April, 2007, there are 3 multi-modality IIT trials under active development. The institution will continue to provide funds to support staff for these IIT trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-11
Application #
8084111
Study Section
Subcommittee G - Education (NCI)
Project Start
2010-06-03
Project End
2013-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
11
Fiscal Year
2010
Total Cost
$93,363
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299
Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603

Showing the most recent 10 out of 807 publications